{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T23:05:05Z","timestamp":1771542305943,"version":"3.50.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":13,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2020MH273"],"award-info":[{"award-number":["ZR2020MH273"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong Province","doi-asserted-by":"publisher","award":["2022CXGC010504-3"],"award-info":[{"award-number":["2022CXGC010504-3"]}],"id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ovarian Res"],"DOI":"10.1186\/s13048-026-01971-9","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:14:28Z","timestamp":1770351268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["LINC00467 mediates PARP inhibitor resistance in high-grade serous ovarian cancer by regulating miR-485-5p\/RAD50 axis"],"prefix":"10.1186","volume":"19","author":[{"given":"Xin","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renzhuo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"1971_CR1","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053\u201364.","journal-title":"Am J Pathol"},{"key":"1971_CR2","doi-asserted-by":"crossref","unstructured":"Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009 Oct 17;374(9698):1371-82.","DOI":"10.1016\/S0140-6736(09)61338-6"},{"issue":"1","key":"1971_CR3","doi-asserted-by":"crossref","first-page":"i58","DOI":"10.1093\/annonc\/mdw088","volume":"27","author":"MA Bookman","year":"2016","unstructured":"Bookman MA. Optimal primary therapy of ovarian cancer. Ann Oncol. 2016;27(1):i58\u201362.","journal-title":"Ann Oncol"},{"key":"1971_CR4","first-page":"280","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux S, Braunstein M, Oza AM. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J Clin. 2019;69:280\u2013304.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"1971_CR5","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2174\/0115665232323373240905104033","volume":"25","author":"J Lu","year":"2025","unstructured":"Lu J, Zhen S, Li X. Characteristics of oxidative Phosphorylation-Related subtypes and construction of a prognostic signature in ovarian cancer. Curr Gene Ther. 2025;25(3):327\u201344.","journal-title":"Curr Gene Ther"},{"key":"1971_CR6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.ygyno.2014.02.039","volume":"133","author":"JF Liu","year":"2014","unstructured":"Liu JF, Konstantinopoulos PA, Matulonis UA. PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014;133:362\u20139.","journal-title":"Gynecol Oncol"},{"key":"1971_CR7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/s41571-018-0055-6","volume":"15","author":"A Ashworth","year":"2018","unstructured":"Ashworth A, Lord CJ. Synthetic lethal therapies for cancer: what\u2019s next after PARP inhibitors? Nat Rev Clin Oncol. 2018;15:564\u201376.","journal-title":"Nat Rev Clin Oncol"},{"key":"1971_CR8","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 2011;12:852\u201361.","journal-title":"Lancet Oncol"},{"key":"1971_CR9","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/S1470-2045(13)70240-7","volume":"14","author":"SK Sandhu","year":"2013","unstructured":"Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A, Kreischer N, Thway K, Gevensleben H, Sun L, Loughney J, Chatterjee M, Toniatti C, Carpenter CL, Iannone R, Kaye SB, de Bono JS, Wenham RM. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2013;14:882\u201392.","journal-title":"Lancet Oncol"},{"key":"1971_CR10","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2017.01.010","volume":"391","author":"Y Tang","year":"2017","unstructured":"Tang Y, Cheung BB, Atmadibrata B, Marshall GM, Dinger ME, Liu PY, Liu T. The regulatory role of long noncoding RNAs in cancer. Cancer Lett. 2017;391:12\u20139.","journal-title":"Cancer Lett"},{"issue":"7","key":"1971_CR11","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.7150\/ijbs.40769","volume":"16","author":"W Lin","year":"2020","unstructured":"Lin W, Zhou Q, Wang CQ, Zhu L, Bi C, Zhang S, Wang X, Jin H. LncRNAs regulate metabolism in cancer. Int J Biol Sci. 2020;16(7):1194\u2013206.","journal-title":"Int J Biol Sci"},{"key":"1971_CR12","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1038\/ng.2771","volume":"45","author":"JR Prensner","year":"2013","unstructured":"Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, Chen W, Han S, Jing X, Cao X, Wang X, Chandler B, Yan W, Siddiqui J, Kunju LP, Dhanasekaran SM, Pienta KJ, Feng FY, Chinnaiyan AM. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI\/SNF complex. Nat Genet. 2013;45:1392\u20138.","journal-title":"Nat Genet"},{"key":"1971_CR13","doi-asserted-by":"crossref","first-page":"9105","DOI":"10.1002\/jcp.27587","volume":"234","author":"X Kong","year":"2019","unstructured":"Kong X, Duan Y, Sang Y, Li Y, Zhang H, Liang Y, Liu Y, Zhang N, Yang Q. LncRNA-CDC6 promotes breast cancer progression and function as CeRNA to target CDC6 by sponging microRNA-215. J Cell Physiol. 2019;234:9105\u201317.","journal-title":"J Cell Physiol"},{"issue":"10","key":"1971_CR14","doi-asserted-by":"crossref","first-page":"829","DOI":"10.2174\/0929866529666220704122019","volume":"29","author":"J Xu","year":"2022","unstructured":"Xu J, Zheng LH, Hong YN, et al. Long Non-coding RNA UCA1 regulates SRPK1 expression through miR- 99b-3p in ovarian cancer. Protein Pept Lett. 2022;29(10):829\u201338.","journal-title":"Protein Pept Lett"},{"issue":"8","key":"1971_CR15","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2174\/0929866530666230607104453","volume":"30","author":"SAM Sherazi","year":"2023","unstructured":"Sherazi SAM, Rafique F, Haris M, et al. Applications of CRISPR Cas-9 in ovarian cancer research. Protein Pept Lett. 2023;30(8):653\u201367.","journal-title":"Protein Pept Lett"},{"key":"1971_CR16","doi-asserted-by":"crossref","first-page":"143969","DOI":"10.1016\/j.gene.2019.143969","volume":"713","author":"Q Guo","year":"2019","unstructured":"Guo Q, Wang L, Zhu L, Lu X, Song Y, Sun J, Wu Z, Shi J, Wang Z, Zhou X. The clinical significance and biological function of LncRNA SOCAR in serous ovarian carcinoma. Gene. 2019;713:143969.","journal-title":"Gene"},{"key":"1971_CR17","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/s41419-018-0908-z","volume":"9","author":"W Yong","year":"2018","unstructured":"Yong W, Yu D, Jun Z, Yachen D, Weiwei W, Midie X, Xingzhu J, Xiaohua W. Long noncoding RNA NEAT1, regulated by LIN28B, promotes cell proliferation and migration through sponging miR-506 in high-grade serous ovarian cancer. Cell Death Dis. 2018;9:861.","journal-title":"Cell Death Dis"},{"key":"1971_CR18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast RC Jr., Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer. 2011;11:719\u201325.","journal-title":"Nat Rev Cancer"},{"key":"1971_CR19","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.2174\/138161212802002823","volume":"18","author":"AV Tinker","year":"2012","unstructured":"Tinker AV, Gelmon K. The role of PARP inhibitors in the treatment of ovarian carcinomas. Curr Pharm Des. 2012;18:3770\u20134.","journal-title":"Curr Pharm Des"},{"key":"1971_CR20","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nrm.2017.48","volume":"18","author":"HHY Chang","year":"2017","unstructured":"Chang HHY, Pannunzio NR, Adachi N, Lieber MR. Non-homologous DNA end joining and alternative pathways to double-strand break repair. Nat Rev Mol Cell Biol. 2017;18:495\u2013506.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1971_CR21","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","volume":"379","author":"K Moore","year":"2018","unstructured":"Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, Gonzalez-Martin A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, Bloomfield R, DiSilvestro P. Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495\u2013505.","journal-title":"N Engl J Med"},{"key":"1971_CR22","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/JCO.2009.26.9589","volume":"28","author":"PC Fong","year":"2010","unstructured":"Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A\u2019Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010;28:2512\u20139.","journal-title":"J Clin Oncol"},{"key":"1971_CR23","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","volume":"20","author":"KP Pennington","year":"2014","unstructured":"Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, Thornton A, Norquist BM, Casadei S, Nord AS, Agnew KJ, Pritchard CC, Scroggins S, Garcia RL, King MC, Swisher EM. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res. 2014;20:764\u201375.","journal-title":"Clin Cancer Res"},{"key":"1971_CR24","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, Gonzalez-Martin A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA, Investigators E-ON. Niraparib maintenance therapy in Platinum-Sensitive, recurrent ovarian cancer. N Engl J Med. 2016;375:2154\u201364.","journal-title":"N Engl J Med"},{"key":"1971_CR25","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O\u2019Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA. A. investigators, Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:1949\u201361.","journal-title":"Lancet"},{"key":"1971_CR26","doi-asserted-by":"crossref","unstructured":"Rui Q, Xu Z, Yang P, He Z. Long noncoding RNA expression patterns in lymph node metastasis in colorectal cancer by microarray. Volume 75. Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie; 2015. pp. 12\u20138.","DOI":"10.1016\/j.biopha.2015.08.003"},{"issue":"1","key":"1971_CR27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12935-022-02733-5","volume":"22","author":"X Chen","year":"2022","unstructured":"Chen X, Luo Q, Xiao Y, Zhu J, Zhang Y, Ding J, Li J. LINC00467: an oncogenic long noncoding RNA. Cancer Cell Int. 2022;22(1):303.","journal-title":"Cancer Cell Int"},{"key":"1971_CR28","doi-asserted-by":"crossref","first-page":"D210","DOI":"10.1093\/nar\/gkr1175","volume":"40","author":"D Bu","year":"2012","unstructured":"Bu D, Yu K, Sun S, Xie C, Skogerbo G, Miao R, Xiao H, Liao Q, Luo H, Zhao G, Zhao H, Liu Z, Liu C, Chen R, Zhao Y. NONCODE v3.0: integrative annotation of long noncoding RNAs. Nucleic Acids Res. 2012;40:D210\u2013215.","journal-title":"Nucleic Acids Res"},{"key":"1971_CR29","doi-asserted-by":"crossref","unstructured":"Ge Q, Jia D, Cen D, Qi Y, Shi C, Li J, Sang L, Yang LJ, He J, Lin A, Chen S, Wang L. Micropeptide ASAP encoded by LINC00467 promotes colorectal cancer progression by directly modulating ATP synthase activity. J Clin Invest. 2021;131(22):e152911.","DOI":"10.1172\/JCI152911"},{"key":"1971_CR30","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1038\/s41388-020-01421-w","volume":"39","author":"Y Zhu","year":"2020","unstructured":"Zhu Y, Li J, Bo H, He D, Xiao M, Xiang L, Gong L, Hu Y, Zhang Y, Cheng Y, Deng L, Zhu R, Ma Y, Cao K. LINC00467 is up-regulated by TDG-mediated acetylation in non-small cell lung cancer and promotes tumor progression. Oncogene. 2020;39:6071\u201384.","journal-title":"Oncogene"},{"issue":"2","key":"1971_CR31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.5937\/jomb0-39708","volume":"42","author":"Z Ji","year":"2023","unstructured":"Ji Z, Zhang J, Zhang L, Yang S, Li Y, Gu L. LINC00467 induces melanoma deterioration by targeting miR-485-5p\/p21 activated kinase 1. J Med Biochem. 2023;42(2):282\u20138.","journal-title":"J Med Biochem"},{"issue":"6","key":"1971_CR32","first-page":"6248","volume":"13","author":"Y Liang","year":"2021","unstructured":"Liang Y, Cheng G, Huang D, Yuan F. Linc00467 promotes invasion and inhibits apoptosis of head and neck squamous cell carcinoma by regulating miR-1285-3p\/TFAP2A. Am J Translational Res. 2021;13(6):6248\u201359.","journal-title":"Am J Translational Res"},{"issue":"3","key":"1971_CR33","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jgh.15201","volume":"36","author":"Z Liu","year":"2021","unstructured":"Liu Z, Yang S, Chen X, Dong S, Zhou S, Xu S. LncRNA LINC00467 acted as an oncogene in esophageal squamous cell carcinoma by accelerating cell proliferation and preventing cell apoptosis via the miR-485-5p\/DPAGT1 axis. J Gastroenterol Hepatol. 2021;36(3):721\u201330.","journal-title":"J Gastroenterol Hepatol"},{"issue":"5","key":"1971_CR34","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.4149\/neo_2020_190927N979","volume":"67","author":"Y Yang","year":"2020","unstructured":"Yang Y, Liu J, Qian X, Li Y, Wang Y, Xu X. miR-485-5p improves the progression of ovarian cancer by targeting SRC in vitro and in vivo. Neoplasma. 2020;67(5):1022\u201331.","journal-title":"Neoplasma"},{"issue":"23","key":"1971_CR35","doi-asserted-by":"crossref","first-page":"10961","DOI":"10.1111\/jcmm.17017","volume":"25","author":"Y Li","year":"2021","unstructured":"Li Y, Wang S, Li P, Li Y, Liu Y, Fang H, Zhang X, Liu Z, Kong B. Rad50 promotes ovarian cancer progression through NF-\u03baB activation. J Cell Mol Med. 2021;25(23):10961\u201372.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"1971_CR36","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s43556-020-00023-y","volume":"1","author":"A Alblihy","year":"2020","unstructured":"Alblihy A, Alabdullah ML, Toss MS, Algethami M, Mongan NP, Rakha EA, Madhusudan S. RAD50 deficiency is a predictor of platinum sensitivity in sporadic epithelial ovarian cancers. Mol Biomed. 2020;1(1):19.","journal-title":"Mol Biomed"},{"key":"1971_CR37","doi-asserted-by":"crossref","first-page":"101206","DOI":"10.1016\/j.mtbio.2024.101206","volume":"28","author":"AE Zetrini","year":"2024","unstructured":"Zetrini AE, Abbasi AZ, He C, Lip H, Alradwan I, Rauth AM, Henderson JT, Wu XY. Targeting DNA damage repair mechanism by using RAD50-silencing SiRNA nanoparticles to enhance radiotherapy in triple negative breast cancer. Mater Today Bio. 2024;28:101206.","journal-title":"Mater Today Bio"},{"issue":"1","key":"1971_CR38","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/s12935-022-02733-5","volume":"22","author":"X Chen","year":"2022","unstructured":"Chen X, Luo Q, Xiao Y, et al. LINC00467: an oncogenic long noncoding RNA. Cancer Cell Int. 2022;22(1):303.","journal-title":"Cancer Cell Int"},{"key":"1971_CR39","doi-asserted-by":"crossref","first-page":"892009","DOI":"10.3389\/fgene.2022.892009","volume":"13","author":"D Wu","year":"2022","unstructured":"Wu D, Li R, Liu J, Zhou C, Jia R. Long noncoding RNA LINC00467: role in various human cancers. Front Genet. 2022;13:892009.","journal-title":"Front Genet"},{"issue":"11","key":"1971_CR40","first-page":"2212","volume":"7","author":"M Kang","year":"2015","unstructured":"Kang M, Ren MP, Zhao L, Li CP, Deng MM. miR-485-5p acts as a negative regulator in gastric cancer progression by targeting flotillin-1. Am J Transl Res. 2015;7(11):2212\u201322.","journal-title":"Am J Transl Res"},{"key":"1971_CR41","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejca.2016.03.005","volume":"60","author":"JA Ledermann","year":"2016","unstructured":"Ledermann JA, Drew Y, Kristeleit RS. Homologous recombination deficiency and ovarian cancer. Eur J Cancer. 2016;60:49\u201358.","journal-title":"Eur J Cancer"},{"key":"1971_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.10.010","volume":"344","author":"P Malaney","year":"2014","unstructured":"Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett. 2014;344:1\u201312.","journal-title":"Cancer Lett"},{"key":"1971_CR43","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/clpt.2008.200","volume":"85","author":"B Rubio-Viqueira","year":"2009","unstructured":"Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients. Clin Pharmacol Ther. 2009;85:217\u201321.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1971_CR44","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12967-022-03405-8","volume":"20","author":"S Abdolahi","year":"2022","unstructured":"Abdolahi S, Ghazvinian Z, Muhammadnejad S, Saleh M, Aghdaei A, H., Baghaei K. Patient-derived xenograft (PDX) models, applications and challenges in cancer research. J Translational Med. 2022;20(1):206.","journal-title":"J Translational Med"},{"key":"1971_CR45","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00016347709158340","volume":"56","author":"M Davy","year":"1977","unstructured":"Davy M, Mossige J, Johannessen JV. Heterologous growth of human ovarian cancer. A new in vivo testing system. Acta Obstet Gynecol Scand. 1977;56:55\u20139.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"1971_CR46","first-page":"2662","volume":"47","author":"BG Ward","year":"1987","unstructured":"Ward BG, Wallace K, Shepherd JH, Balkwill FR. Intraperitoneal xenografts of human epithelial ovarian cancer in nude mice. Cancer Res. 1987;47:2662\u20137.","journal-title":"Cancer Res"},{"issue":"1","key":"1971_CR47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-019-1100-5","volume":"18","author":"L Bian","year":"2019","unstructured":"Bian L, Meng Y, Zhang M, Li D. MRE11-RAD50-NBS1 complex alterations and DNA damage response: implications for cancer treatment. Mol Cancer. 2019;18(1):169.","journal-title":"Mol Cancer"},{"issue":"1","key":"1971_CR48","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41523-021-00350-5","volume":"7","author":"A Alblihy","year":"2021","unstructured":"Alblihy A, Shoqafi A, Toss MS, et al. Untangling the clinicopathological significance of MRE11-RAD50-NBS1 complex in sporadic breast cancers. NPJ Breast Cancer. 2021;7(1):143.","journal-title":"NPJ Breast Cancer"}],"container-title":["Journal of Ovarian Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13048-026-01971-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01971-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13048-026-01971-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T22:06:03Z","timestamp":1771538763000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13048-026-01971-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1971"],"URL":"https:\/\/doi.org\/10.1186\/s13048-026-01971-9","relation":{},"ISSN":["1757-2215"],"issn-type":[{"value":"1757-2215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"20 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"71"}}